CEBPZ and acute myeloid leukemia: These two cytogenetic subgroups (collectively referred to as CBF-AML) have also been associated with a relatively favorable prognosis compared with patients with normal or adverse karyotypes, and clinical studies have often stratified these patients together, into one favorable-risk prognostic factor, and treated them similarly [4].